Dexmedetomidine Ameliorates Lidocaine-Induced Spinal Neurotoxicity Via Inhibiting Glutamate Release and the PKC Pathway

Haiping Xu,Baisong Zhao,Yingjun She,Xingrong Song
DOI: https://doi.org/10.1016/j.neuro.2018.09.004
IF: 4.398
2018-01-01
NeuroToxicology
Abstract:Dexmedetomidine, a selective alpha(2) adrenergic agonist, has been shown to have neuroprotective and anti-apoptotic effects. To further investigate the underlying mechanisms, we used a rat model of spinal neurotoxicity induced by intrathecal administration of lidocaine. Four days after intrathecal catheter implantation, rats received an intraperitoneal injection of various doses of dexmedetomidine before an intrathecal injection of 20 mu L 10% lidocaine. Dexmedetomidine-pretreated rats were also exposed to a selective alpha 2-adrenergic antagonist (yohimbine) or a specific protein kinase C (PKC) inhibitor (GO 6983) that selectively inhibits several PKC isoforms. Lidocaine injection significantly damaged the spinal cord: hind limb locomotor function was reduced and tail flick latency was prolonged; significant spinal cord damage and neuronal apoptosis were identified using histological and TUNEL staining assays; increased glutamate release was detected using high performance liquid chromatography (HPLC) analysis; and increased expression of PKC and PKC beta I was detected using Western blotting analysis. Pretreatment with dexmedetomidine ameliorated all of the lidocaine-induced effects; however, this protection was abolished when yohimbine or Go 6983 was injected together with dexmedetomidine. Our results indicate that dexmedetomidine protects the spinal cord from lidocaine-induced spinal neurotoxicity through regulating PKC expression and glutamate release.
What problem does this paper attempt to address?